Targovax is a biotechnology company developing oncolytic viruses and cancer vaccines to activate the immune system and fight cancer. The company has two clinical programs, ONCOS-102, an oncolytic virus, and TG, a neoantigen vaccine targeting mutated RAS cancers. Targovax is conducting clinical trials for both programs and has a strong cash position to complete its planned clinical trials into 2019.
Targovax is a biotechnology company developing oncolytic viruses and cancer vaccines to activate the immune system and fight cancer. The company has two clinical programs, ONCOS-102, an oncolytic virus, and TG, a neoantigen vaccine targeting mutated RAS cancers. Targovax is conducting clinical trials for both programs and has a strong cash position to complete its planned clinical trials into 2019.
This report discusses Targovax's oncolytic virus and neoantigen vaccine programs for cancer immunotherapy. ONCOS-102, an oncolytic virus, has shown signs of efficacy in early clinical trials and is being studied in combination with chemotherapy for mesothelioma. Targovax is also developing TG, a neoantigen vaccine targeting mutated RAS cancers which accounts for many pancreatic and colorectal cancer cases. Targovax has an ongoing clinical program and aims to become a frontline treatment for mesothelioma with ONCOS-102 based on positive early data.
The document provides an overview and highlights from Targovax's first quarter 2018 presentation. Some key points:
- Targovax has two immuno-oncology programs in clinical development, ONCOS-102 and ONCOS TG.
- In the mesothelioma trial, the safety lead-in cohort of 6 patients was completed without safety concerns and showed signs of immune activation and early clinical responses in 3 patients.
- Targovax has a sound financial position with cash to fund its planned clinical program into 2019 and is listed on the Oslo Stock Exchange.
This document discusses Targovax's strategy for outsourcing clinical manufacturing and quality control activities. As a virtual biotech company, Targovax outsources all development, manufacturing, and testing of its three investigational medicinal products - a peptide vaccine (TG), recombinant GM-CSF, and an oncolytic virus (ONCOS-102). The document describes Targovax's current contract manufacturing organizations for clinical supply and its plans to select new partners to support late-stage clinical trials and commercialization. It provides an overview of Targovax's multi-stage process for evaluating and selecting these strategic contract development and manufacturing partners.
1) The document discusses Targovax's clinical programs targeting cancer through immune activation, including their ONCOS oncolytic virus and TG RAS neoantigen vaccine.
2) Early clinical trials of ONCOS-102 demonstrated immune activation and clinical activity in patients with various solid tumors.
3) Targovax is conducting additional trials of ONCOS-102 in combination with checkpoint inhibitors in indications like mesothelioma and peritoneal cancers.
4) The TG vaccine targets mutated RAS neoantigens, which are present in many cancer types, and aims to induce T-cell responses against patient-specific tumors.
This document summarizes Targovax's approach to activating the immune system to fight cancer. It discusses moving from sequential treatment strategies like surgery, radiation, and chemotherapy to a combination approach harnessing the immune system. Targovax's focus is on immune activators like oncolytic viruses and vaccines to make cancer visible to the immune system. The document outlines Targovax's clinical programs using oncolytic viruses ONCOS and therapeutic cancer vaccine TG, including current and planned trials in cancers like mesothelioma, melanoma, and colorectal cancer. Early data from a phase I/II trial of ONCOS-102 in mesothelioma shows safety and signs of efficacy.
This document provides an overview of Targovax's clinical programs for their two immuno-oncology platforms: ONCOS oncolytic virus and TG mutRAS neoantigen vaccine. For TG, encouraging survival data was seen in a previous trial in resected pancreatic cancer patients, with 20% 10-year survival. This is now being validated in an ongoing phase I/II trial, with 90% of patients showing immune activation against RAS. For ONCOS, phase I data showed it increased tumor-infiltrating CD8+ T-cells and this correlated with improved survival. In mouse models, ONCOS enhanced the efficacy of checkpoint inhibitors against melanoma. Targovax has an ongoing clinical program with these
- Targovax has developed a peptide vaccine called TG01 that targets RAS mutations found in over 90% of pancreatic cancers.
- In clinical trials, TG01 has shown an ability to induce both CD4+ and CD8+ T-cell immune responses against mutant RAS in over 90% of patients. Patients who responded immunologically showed a 3x longer median survival time.
- Interim data from an ongoing Phase I/II trial combining TG01 with chemotherapy in resected pancreatic cancer patients showed 100% 1-year survival for the second cohort and a median survival of 33.1 months, compared to a historical control of 27.6 months.
Targovax is a biotechnology company developing oncolytic viruses and cancer vaccines to activate the immune system and fight cancer. The company has two clinical programs, ONCOS-102, an oncolytic virus, and TG, a neoantigen vaccine targeting mutated RAS cancers. Targovax is conducting clinical trials for both programs and has a strong cash position to complete its planned clinical trials into 2019.
This report discusses Targovax's oncolytic virus and neoantigen vaccine programs for cancer immunotherapy. ONCOS-102, an oncolytic virus, has shown signs of efficacy in early clinical trials and is being studied in combination with chemotherapy for mesothelioma. Targovax is also developing TG, a neoantigen vaccine targeting mutated RAS cancers which accounts for many pancreatic and colorectal cancer cases. Targovax has an ongoing clinical program and aims to become a frontline treatment for mesothelioma with ONCOS-102 based on positive early data.
The document provides an overview and highlights from Targovax's first quarter 2018 presentation. Some key points:
- Targovax has two immuno-oncology programs in clinical development, ONCOS-102 and ONCOS TG.
- In the mesothelioma trial, the safety lead-in cohort of 6 patients was completed without safety concerns and showed signs of immune activation and early clinical responses in 3 patients.
- Targovax has a sound financial position with cash to fund its planned clinical program into 2019 and is listed on the Oslo Stock Exchange.
This document discusses Targovax's strategy for outsourcing clinical manufacturing and quality control activities. As a virtual biotech company, Targovax outsources all development, manufacturing, and testing of its three investigational medicinal products - a peptide vaccine (TG), recombinant GM-CSF, and an oncolytic virus (ONCOS-102). The document describes Targovax's current contract manufacturing organizations for clinical supply and its plans to select new partners to support late-stage clinical trials and commercialization. It provides an overview of Targovax's multi-stage process for evaluating and selecting these strategic contract development and manufacturing partners.
1) The document discusses Targovax's clinical programs targeting cancer through immune activation, including their ONCOS oncolytic virus and TG RAS neoantigen vaccine.
2) Early clinical trials of ONCOS-102 demonstrated immune activation and clinical activity in patients with various solid tumors.
3) Targovax is conducting additional trials of ONCOS-102 in combination with checkpoint inhibitors in indications like mesothelioma and peritoneal cancers.
4) The TG vaccine targets mutated RAS neoantigens, which are present in many cancer types, and aims to induce T-cell responses against patient-specific tumors.
This document summarizes Targovax's approach to activating the immune system to fight cancer. It discusses moving from sequential treatment strategies like surgery, radiation, and chemotherapy to a combination approach harnessing the immune system. Targovax's focus is on immune activators like oncolytic viruses and vaccines to make cancer visible to the immune system. The document outlines Targovax's clinical programs using oncolytic viruses ONCOS and therapeutic cancer vaccine TG, including current and planned trials in cancers like mesothelioma, melanoma, and colorectal cancer. Early data from a phase I/II trial of ONCOS-102 in mesothelioma shows safety and signs of efficacy.
This document provides an overview of Targovax's clinical programs for their two immuno-oncology platforms: ONCOS oncolytic virus and TG mutRAS neoantigen vaccine. For TG, encouraging survival data was seen in a previous trial in resected pancreatic cancer patients, with 20% 10-year survival. This is now being validated in an ongoing phase I/II trial, with 90% of patients showing immune activation against RAS. For ONCOS, phase I data showed it increased tumor-infiltrating CD8+ T-cells and this correlated with improved survival. In mouse models, ONCOS enhanced the efficacy of checkpoint inhibitors against melanoma. Targovax has an ongoing clinical program with these
- Targovax has developed a peptide vaccine called TG01 that targets RAS mutations found in over 90% of pancreatic cancers.
- In clinical trials, TG01 has shown an ability to induce both CD4+ and CD8+ T-cell immune responses against mutant RAS in over 90% of patients. Patients who responded immunologically showed a 3x longer median survival time.
- Interim data from an ongoing Phase I/II trial combining TG01 with chemotherapy in resected pancreatic cancer patients showed 100% 1-year survival for the second cohort and a median survival of 33.1 months, compared to a historical control of 27.6 months.
Targovax has two immuno-oncology programs - ONCOS, an oncolytic virus, and TG, a RAS neoantigen vaccine. TG has shown promising results in pancreatic cancer trials, with 20% 10-year survival in previous trials. An ongoing phase I/II trial is validating these results with adjuvant chemotherapy. ONCOS has demonstrated the ability to increase tumor-infiltrating T-cells in early trials. Targovax has a broad clinical program with several upcoming data readouts in 2017-2018 from trials in melanoma, mesothelioma, ovarian/colorectal, prostate, and pancreatic/colorectal cancers.
This document provides an overview of Targovax, a biotechnology company developing immunotherapy treatments for cancer. It summarizes Targovax's two platform technologies: ONCOS-102, an oncolytic virus that selectively infects and lyses cancer cells to trigger an immune response, and TG neoantigen vaccines that target specific cancer mutations to generate T-cells to kill cancer cells. The document outlines Targovax's clinical development plans and timelines across six clinical trials in several cancer indications. It also reviews the company's financial position and shareholder base, noting a strong cash runway into 2019 to complete the planned clinical program.
Targovax is developing immunotherapies to help the immune system fight cancer. They have six ongoing clinical trials combining their oncolytic adenovirus or peptide vaccines with checkpoint inhibitors or chemotherapy. They expect readouts from four of these trials in 2017-2018, which will be important value inflection points. Encouraging survival data was seen in a Phase I/II trial of their peptide vaccine TG01 in resected pancreatic cancer patients.
1706 ir deck full w_appendix v1_cmd_v6_uten appendixtargovax2017
The document summarizes a capital markets update presentation by Targovax. It discusses Targovax's two immunotherapy platforms - ONCOS-102, an oncolytic virus, and TG01, a peptide cancer vaccine. For ONCOS-102, the virus is injected into tumors where it stimulates an immune response by releasing cancer antigens. TG01 mimics antigens to stimulate "killer" T-cells. Early clinical trial results for ONCOS-102 showed increased tumor-infiltrating T-cells and systemic immune responses in cancer patients. Targovax is pursuing multiple clinical trials to combine its immunotherapies with other treatments.
Targovax is developing two cancer immunotherapy drugs - ONCOS-102, an oncolytic virus, and TG01, a neoantigen vaccine. Data from clinical trials of ONCOS-102 showed it activated patients' immune systems against their tumors. Targovax has an ongoing clinical program testing ONCOS-102 in various cancer types and combinations. TG01 targets RAS mutations in pancreatic cancer and showed encouraging long-term survival rates in previous trials. A recent trial combining TG01 with chemotherapy showed improved median and 2-year survival over historical controls. Targovax is seeking a partner to advance TG01 into a late-stage trial aimed at registration.
Targovax presented highlights from Q1 2017, including encouraging survival data from a phase I/II trial of TG01 in pancreatic cancer. 68% of patients were still alive after 2 years, compared to historical rates of 30-53%. Targovax will present further clinical data on TG01 at ASCO in June. The company initiated an exploratory trial of TG01 in colorectal cancer and has six clinical trials ongoing or planned in 2017-2018 across cancer indications. Financially, Targovax has cash of NOK 147M and an operating expenses run rate of NOK 104M annually based on the last four quarters.
Targovax presented its 3Q 2017 results, highlighting ongoing clinical trials with its two platforms: ONCOS-102, an oncolytic virus in Phase I/II trials in combination with other therapies, and TG01, a neoantigen vaccine showing encouraging survival data in a Phase I/II trial in pancreatic cancer. Targovax has a cash runway into 2019 to fund its clinical programs and is listed on the Oslo Stock Exchange with a market capitalization of around NOK 930 million.
1706 ir deck full w_appendix v1_cmd_v12_netttargovax2017
The document discusses Targovax's TG01 peptide vaccine platform. TG01 primes the immune system to recognize and destroy cancer cells with RAS mutations through a cocktail of 7 peptides covering common RAS mutations. Earlier trials in pancreatic cancer showed encouraging median and 1-year survival rates compared to historical controls when TG01 was administered with GM-CSF adjuvant. Long-term survival data also correlated with immune responses detected following vaccination.
The document provides an overview of Targovax's clinical programs for ONCOS-102 and TG01. For ONCOS-102, a Phase I/II trial in ovarian and colorectal cancer in combination with durvalumab was initiated in Q3 2017. Encouraging survival and immune response data was reported from the ongoing Phase I/II trial of TG01 in resected pancreatic cancer. Targovax is developing these programs to boost the effectiveness of immunotherapy and has clinical readouts expected in 2017-2019.
Targovax is developing immunotherapies to enable the immune system to kill cancer cells. They have two platforms: oncolytic viruses and peptide vaccines. Their peptide vaccine TG01 showed encouraging 2-year survival data in a Phase I/II trial in pancreatic cancer patients, with a survival rate higher than historical controls. Their oncolytic virus ONCOS-102 is in a Phase I trial in CPI-refractory melanoma patients to see if it can activate the immune system and make those patients responsive to checkpoint inhibitors again. Targovax has multiple clinical readouts expected in 2017 and 2018 that could be value inflection points.
Arming the patient's immune system to fight cancertargovax2017
This document summarizes a presentation by Targovax CEO Øystein Soug at a healthcare conference on December 15, 2016. Targovax is developing immunotherapies to enable the immune system to kill cancer cells, including oncolytic viruses, peptide vaccines, cell therapies, and checkpoint inhibitors. The presentation outlines Targovax's clinical trial pipeline and strategy, including trials of ONCOS-102 in CPI-refractory melanoma and mesothelioma and TG01 in resected pancreatic and colorectal cancers. Near-term value drivers include TG01 two-year survival data in pancreatic cancer in 1H2017 and ONCOS-102 interim data in melanoma in 2H2017.
Targovax is developing two complementary and highly targeted approaches to cancer immunotherapy: a peptide-based targeted immunotherapy platform for patients with RAS-mutated cancers and a virus-based oncolytic immunotherapy platform based on engineered oncolytic viruses armed with potent immune-stimulating transgenes for patients with solid tumors.
Targovax presentation december 2017 carnegietargovax2017
Targovax provided an overview of its clinical programs for its two immuno-oncology platforms: ONCOS oncolytic virus and TG mutRAS neoantigen vaccine. For ONCOS, interim data from ongoing phase I/II trials in several solid tumors was highlighted. For TG, encouraging survival data from a phase I/II trial in resected pancreatic cancer was summarized. Upcoming clinical readouts and trial initiations in 2017-2018 were outlined for both platforms.
Targovax is developing cancer immunotherapies using their TG technology to arm the immune system to fight RAS mutated cancers. Their lead candidate TG01 is in Phase I/II trials in combination with chemotherapy for resected pancreatic cancer, showing promising early survival data. Targovax has a broad clinical program with upcoming data readouts evaluating TG01 in additional cancer types and TG02 entering Phase I trials. Their therapeutic cancer vaccines target specific RAS mutations found in many cancers, offering a potential new treatment approach.
This corporate presentation summarizes PharmaMar's pipeline and strategy:
- PharmaMar is a biotech company focused on developing marine-derived oncology drugs. It has a fully integrated platform from discovery to commercialization.
- The pipeline includes Yondelis® for soft tissue sarcoma and ovarian cancer, Aplidin® for multiple myeloma, and PM1183 which is being studied in small cell lung cancer, platinum-resistant ovarian cancer, and BRCA breast cancer.
- PM1183 has shown promising results in early clinical trials, achieving a 67% response rate in small cell lung cancer. Phase III trials are ongoing in platinum-resistant ovarian cancer.
Scientia Advisors Impact Of Microarray In M Dx Oct 2008glorikian
The document summarizes a report by Scientia Advisors on the impact of DNA microarrays on molecular diagnostics. It provides an overview of the microarray market for molecular diagnostics, which is currently small but growing rapidly. Key drivers of growth include the ability of microarrays to profile multiple genes and pathways involved in complex diseases like cancer. The document also discusses regulatory requirements, reimbursement challenges, examples of microarray-based diagnostic tests, and emerging array technologies that could increase clinical adoption if assay time, ease of use, and reproducibility are improved.
T-Cell Immunotherapy Pipeline Analysis 2016 by P&S Market ResearchAryan Mishra
The study analyzed that the T-cell immunotherapy pipeline comprised of 139 therapeutic candidates, of which 16 are in Phase II stage of development. The high prevalence of cancer across the globe fuels the extensive research and development for the T-cell immunotherapeutic.
2013 US Tumor Marker Testing Market: Opportunities and Strategies for SupplierReportsnReports
This 620-page report provides a comprehensive analysis of the US tumor marker testing market, including cancer statistics, current and emerging diagnostic tests, instrumentation technologies, test volume and sales forecasts through 2023 for various market segments. It highlights major opportunities for suppliers in reagent kits, instrumentation, automation, and software. The report profiles current and emerging suppliers and provides strategic recommendations to support business strategies.
Cancer targeted therapy market & clinical insight 2015KuicK Research
“Cancer Targeted Therapy Market & Clinical Insight” Report Highlight:
Introduction & Categorization of Cancer Targeted Therapies
Mechanism of Cancer Targeted Tyrosine Kinase, Vaccines, Oncogenes Inhibitors, Monoclonal Antibodies
Cancer Targeted Therapy Clinical Pipeline by Company, Indication & Phase
Clinical Insight on More Than 1200 Cancer Targeted Therapies in Pipeline
Clinical Insight & Patent Analysis of Marketed Cancer Targeted Therapies
Global Cancer Targeted Therapeutics Market Dynamics
Future Prospects of Cancer Targeted Therapies
Cancer targeted therapy market & clinical insight 2015KuicK Research
“Cancer Targeted Therapy Market & Clinical Insight” Report Highlight:
Introduction & Categorization of Cancer Targeted Therapies
Mechanism of Cancer Targeted Tyrosine Kinase, Vaccines, Oncogenes Inhibitors, Monoclonal Antibodies
Cancer Targeted Therapy Clinical Pipeline by Company, Indication & Phase
Clinical Insight on More Than 1200 Cancer Targeted Therapies in Pipeline
Clinical Insight & Patent Analysis of Marketed Cancer Targeted Therapies
Global Cancer Targeted Therapeutics Market Dynamics
Future Prospects of Cancer Targeted Therapies
Targovax provides a summary of their company presentation on activating the immune system to fight cancer. They have two clinical programs, ONCOS oncolytic virus and TG neoantigen vaccine. ONCOS has ongoing clinical trials in mesothelioma, melanoma, ovarian and colorectal cancers. Early results show immune activation and clinical activity. Their focus is developing ONCOS as the lead product, with mesothelioma as the potential initial indication due to its orphan drug designation. Financially, Targovax has sufficient cash into the second half of 2019 to complete their planned clinical program.
1) The document discusses Targovax's clinical programs using oncolytic viruses and neoantigen vaccines to activate a patient's immune system to fight cancer.
2) Targovax has two lead programs - ONCOS, an oncolytic virus, and TG, a neoantigen vaccine. ONCOS has several ongoing clinical trials and TG has one ongoing trial in colorectal cancer.
3) Preliminary data from a TG trial in pancreatic cancer showed increased median overall and disease-free survival compared to historical controls, suggesting efficacy.
Targovax has two immuno-oncology programs - ONCOS, an oncolytic virus, and TG, a RAS neoantigen vaccine. TG has shown promising results in pancreatic cancer trials, with 20% 10-year survival in previous trials. An ongoing phase I/II trial is validating these results with adjuvant chemotherapy. ONCOS has demonstrated the ability to increase tumor-infiltrating T-cells in early trials. Targovax has a broad clinical program with several upcoming data readouts in 2017-2018 from trials in melanoma, mesothelioma, ovarian/colorectal, prostate, and pancreatic/colorectal cancers.
This document provides an overview of Targovax, a biotechnology company developing immunotherapy treatments for cancer. It summarizes Targovax's two platform technologies: ONCOS-102, an oncolytic virus that selectively infects and lyses cancer cells to trigger an immune response, and TG neoantigen vaccines that target specific cancer mutations to generate T-cells to kill cancer cells. The document outlines Targovax's clinical development plans and timelines across six clinical trials in several cancer indications. It also reviews the company's financial position and shareholder base, noting a strong cash runway into 2019 to complete the planned clinical program.
Targovax is developing immunotherapies to help the immune system fight cancer. They have six ongoing clinical trials combining their oncolytic adenovirus or peptide vaccines with checkpoint inhibitors or chemotherapy. They expect readouts from four of these trials in 2017-2018, which will be important value inflection points. Encouraging survival data was seen in a Phase I/II trial of their peptide vaccine TG01 in resected pancreatic cancer patients.
1706 ir deck full w_appendix v1_cmd_v6_uten appendixtargovax2017
The document summarizes a capital markets update presentation by Targovax. It discusses Targovax's two immunotherapy platforms - ONCOS-102, an oncolytic virus, and TG01, a peptide cancer vaccine. For ONCOS-102, the virus is injected into tumors where it stimulates an immune response by releasing cancer antigens. TG01 mimics antigens to stimulate "killer" T-cells. Early clinical trial results for ONCOS-102 showed increased tumor-infiltrating T-cells and systemic immune responses in cancer patients. Targovax is pursuing multiple clinical trials to combine its immunotherapies with other treatments.
Targovax is developing two cancer immunotherapy drugs - ONCOS-102, an oncolytic virus, and TG01, a neoantigen vaccine. Data from clinical trials of ONCOS-102 showed it activated patients' immune systems against their tumors. Targovax has an ongoing clinical program testing ONCOS-102 in various cancer types and combinations. TG01 targets RAS mutations in pancreatic cancer and showed encouraging long-term survival rates in previous trials. A recent trial combining TG01 with chemotherapy showed improved median and 2-year survival over historical controls. Targovax is seeking a partner to advance TG01 into a late-stage trial aimed at registration.
Targovax presented highlights from Q1 2017, including encouraging survival data from a phase I/II trial of TG01 in pancreatic cancer. 68% of patients were still alive after 2 years, compared to historical rates of 30-53%. Targovax will present further clinical data on TG01 at ASCO in June. The company initiated an exploratory trial of TG01 in colorectal cancer and has six clinical trials ongoing or planned in 2017-2018 across cancer indications. Financially, Targovax has cash of NOK 147M and an operating expenses run rate of NOK 104M annually based on the last four quarters.
Targovax presented its 3Q 2017 results, highlighting ongoing clinical trials with its two platforms: ONCOS-102, an oncolytic virus in Phase I/II trials in combination with other therapies, and TG01, a neoantigen vaccine showing encouraging survival data in a Phase I/II trial in pancreatic cancer. Targovax has a cash runway into 2019 to fund its clinical programs and is listed on the Oslo Stock Exchange with a market capitalization of around NOK 930 million.
1706 ir deck full w_appendix v1_cmd_v12_netttargovax2017
The document discusses Targovax's TG01 peptide vaccine platform. TG01 primes the immune system to recognize and destroy cancer cells with RAS mutations through a cocktail of 7 peptides covering common RAS mutations. Earlier trials in pancreatic cancer showed encouraging median and 1-year survival rates compared to historical controls when TG01 was administered with GM-CSF adjuvant. Long-term survival data also correlated with immune responses detected following vaccination.
The document provides an overview of Targovax's clinical programs for ONCOS-102 and TG01. For ONCOS-102, a Phase I/II trial in ovarian and colorectal cancer in combination with durvalumab was initiated in Q3 2017. Encouraging survival and immune response data was reported from the ongoing Phase I/II trial of TG01 in resected pancreatic cancer. Targovax is developing these programs to boost the effectiveness of immunotherapy and has clinical readouts expected in 2017-2019.
Targovax is developing immunotherapies to enable the immune system to kill cancer cells. They have two platforms: oncolytic viruses and peptide vaccines. Their peptide vaccine TG01 showed encouraging 2-year survival data in a Phase I/II trial in pancreatic cancer patients, with a survival rate higher than historical controls. Their oncolytic virus ONCOS-102 is in a Phase I trial in CPI-refractory melanoma patients to see if it can activate the immune system and make those patients responsive to checkpoint inhibitors again. Targovax has multiple clinical readouts expected in 2017 and 2018 that could be value inflection points.
Arming the patient's immune system to fight cancertargovax2017
This document summarizes a presentation by Targovax CEO Øystein Soug at a healthcare conference on December 15, 2016. Targovax is developing immunotherapies to enable the immune system to kill cancer cells, including oncolytic viruses, peptide vaccines, cell therapies, and checkpoint inhibitors. The presentation outlines Targovax's clinical trial pipeline and strategy, including trials of ONCOS-102 in CPI-refractory melanoma and mesothelioma and TG01 in resected pancreatic and colorectal cancers. Near-term value drivers include TG01 two-year survival data in pancreatic cancer in 1H2017 and ONCOS-102 interim data in melanoma in 2H2017.
Targovax is developing two complementary and highly targeted approaches to cancer immunotherapy: a peptide-based targeted immunotherapy platform for patients with RAS-mutated cancers and a virus-based oncolytic immunotherapy platform based on engineered oncolytic viruses armed with potent immune-stimulating transgenes for patients with solid tumors.
Targovax presentation december 2017 carnegietargovax2017
Targovax provided an overview of its clinical programs for its two immuno-oncology platforms: ONCOS oncolytic virus and TG mutRAS neoantigen vaccine. For ONCOS, interim data from ongoing phase I/II trials in several solid tumors was highlighted. For TG, encouraging survival data from a phase I/II trial in resected pancreatic cancer was summarized. Upcoming clinical readouts and trial initiations in 2017-2018 were outlined for both platforms.
Targovax is developing cancer immunotherapies using their TG technology to arm the immune system to fight RAS mutated cancers. Their lead candidate TG01 is in Phase I/II trials in combination with chemotherapy for resected pancreatic cancer, showing promising early survival data. Targovax has a broad clinical program with upcoming data readouts evaluating TG01 in additional cancer types and TG02 entering Phase I trials. Their therapeutic cancer vaccines target specific RAS mutations found in many cancers, offering a potential new treatment approach.
This corporate presentation summarizes PharmaMar's pipeline and strategy:
- PharmaMar is a biotech company focused on developing marine-derived oncology drugs. It has a fully integrated platform from discovery to commercialization.
- The pipeline includes Yondelis® for soft tissue sarcoma and ovarian cancer, Aplidin® for multiple myeloma, and PM1183 which is being studied in small cell lung cancer, platinum-resistant ovarian cancer, and BRCA breast cancer.
- PM1183 has shown promising results in early clinical trials, achieving a 67% response rate in small cell lung cancer. Phase III trials are ongoing in platinum-resistant ovarian cancer.
Scientia Advisors Impact Of Microarray In M Dx Oct 2008glorikian
The document summarizes a report by Scientia Advisors on the impact of DNA microarrays on molecular diagnostics. It provides an overview of the microarray market for molecular diagnostics, which is currently small but growing rapidly. Key drivers of growth include the ability of microarrays to profile multiple genes and pathways involved in complex diseases like cancer. The document also discusses regulatory requirements, reimbursement challenges, examples of microarray-based diagnostic tests, and emerging array technologies that could increase clinical adoption if assay time, ease of use, and reproducibility are improved.
T-Cell Immunotherapy Pipeline Analysis 2016 by P&S Market ResearchAryan Mishra
The study analyzed that the T-cell immunotherapy pipeline comprised of 139 therapeutic candidates, of which 16 are in Phase II stage of development. The high prevalence of cancer across the globe fuels the extensive research and development for the T-cell immunotherapeutic.
2013 US Tumor Marker Testing Market: Opportunities and Strategies for SupplierReportsnReports
This 620-page report provides a comprehensive analysis of the US tumor marker testing market, including cancer statistics, current and emerging diagnostic tests, instrumentation technologies, test volume and sales forecasts through 2023 for various market segments. It highlights major opportunities for suppliers in reagent kits, instrumentation, automation, and software. The report profiles current and emerging suppliers and provides strategic recommendations to support business strategies.
Cancer targeted therapy market & clinical insight 2015KuicK Research
“Cancer Targeted Therapy Market & Clinical Insight” Report Highlight:
Introduction & Categorization of Cancer Targeted Therapies
Mechanism of Cancer Targeted Tyrosine Kinase, Vaccines, Oncogenes Inhibitors, Monoclonal Antibodies
Cancer Targeted Therapy Clinical Pipeline by Company, Indication & Phase
Clinical Insight on More Than 1200 Cancer Targeted Therapies in Pipeline
Clinical Insight & Patent Analysis of Marketed Cancer Targeted Therapies
Global Cancer Targeted Therapeutics Market Dynamics
Future Prospects of Cancer Targeted Therapies
Cancer targeted therapy market & clinical insight 2015KuicK Research
“Cancer Targeted Therapy Market & Clinical Insight” Report Highlight:
Introduction & Categorization of Cancer Targeted Therapies
Mechanism of Cancer Targeted Tyrosine Kinase, Vaccines, Oncogenes Inhibitors, Monoclonal Antibodies
Cancer Targeted Therapy Clinical Pipeline by Company, Indication & Phase
Clinical Insight on More Than 1200 Cancer Targeted Therapies in Pipeline
Clinical Insight & Patent Analysis of Marketed Cancer Targeted Therapies
Global Cancer Targeted Therapeutics Market Dynamics
Future Prospects of Cancer Targeted Therapies
Targovax provides a summary of their company presentation on activating the immune system to fight cancer. They have two clinical programs, ONCOS oncolytic virus and TG neoantigen vaccine. ONCOS has ongoing clinical trials in mesothelioma, melanoma, ovarian and colorectal cancers. Early results show immune activation and clinical activity. Their focus is developing ONCOS as the lead product, with mesothelioma as the potential initial indication due to its orphan drug designation. Financially, Targovax has sufficient cash into the second half of 2019 to complete their planned clinical program.
1) The document discusses Targovax's clinical programs using oncolytic viruses and neoantigen vaccines to activate a patient's immune system to fight cancer.
2) Targovax has two lead programs - ONCOS, an oncolytic virus, and TG, a neoantigen vaccine. ONCOS has several ongoing clinical trials and TG has one ongoing trial in colorectal cancer.
3) Preliminary data from a TG trial in pancreatic cancer showed increased median overall and disease-free survival compared to historical controls, suggesting efficacy.
This document provides an overview of Targovax, a biotech company developing immunotherapies for cancer. It summarizes their two platforms: ONCOS-102, an oncolytic virus, and TG, a neoantigen cancer vaccine targeting RAS mutations. For ONCOS-102, phase 1 data showed it can activate the immune system against tumors. Targovax is conducting multiple clinical trials of ONCOS-102 in combination with other therapies. For TG, earlier phase 1 trials showed a 20% 10-year survival rate in pancreatic cancer patients. A recent phase 1/2 trial in pancreatic cancer showed encouraging survival and safety data. Targovax is seeking a partner to advance TG into a
Targovax is developing two immunotherapy platforms - ONCOS-102, an oncolytic virus, and TG01, a peptide vaccine targeting RAS mutations. Early phase clinical trial data shows promise for both platforms. ONCOS-102 increased tumor-infiltrating CD8+ T-cells in 11 of 12 cancer patients and induced systemic anti-tumor immune responses. TG01 shows a median survival of 33.1 months in a phase I/II pancreatic cancer trial compared to historical controls of 27.6 months. Targovax has initiated six new clinical trials to further evaluate these platforms alone and in combination with other therapies.
Targovax Next generation immune activators for solid tumorsRoarFredriksen1
Targovax (OSE:TRVX) is a clinical stage immuno-oncology company developing immune activators to target hard-to-treat solid tumors. Targovax’s focus is to activate the patient’s immune system to fight cancer, and to bring benefit to cancer patients with few available treatment alternatives. Targovax is developing its product candidates in different cancer indications, including melanoma, mesothelioma, and multiple myeloma, and has demonstrated a favorable safety and tolerability profile.
Targovax’s lead clinical candidate, ONCOS-102, is a genetically modified oncolytic adenovirus, which has been engineered to selectively infect cancer cells and activate the immune system against the tumor. Following very encouraging clinical data in several indications, both as monotherapy and in combinations, ONCOS-102 is progressing into a randomized phase 2 trial in melanoma patients resistant to PD-1 checkpoint inhibitor treatment.
Building on successful clinical studies which have provided deep mechanistic insights into the tumor biology and the human immune systems, Targovax is researching circular RNA (circRNA) as novel cancer medicines. In addition, Targovax has a KRAS immunotherapy program, with lead cancer vaccine candidate, TG01, expected to enter the clinic in an enhanced format in the second half of 2022. Together this provides Targovax with a rich pipeline of innovative future immunotherapy product candidates to follow ONCOS-102.
1708 2 q presentation v6 uten back-upstargovax2017
This document provides a 3-sentence summary of a presentation by Targovax, a biotech company developing immunotherapies to treat cancer:
Targovax is developing two immunotherapy platforms, ONCOS-102 oncolytic virus and TG01 RAS peptide vaccine, to boost immune responses against cancer and has clinical trials ongoing or planned in several cancer types including pancreatic, melanoma, mesothelioma and others.
The presentation highlights interim clinical data from TG01 showing improved survival outcomes compared to historical controls in resected pancreatic cancer patients and outlines the company's clinical development plans and timelines over the next two years with multiple data readouts expected.
Targovax has sufficient cash runway into
This document discusses Targovax's focus on immune activators to treat cancer. It summarizes:
1) Targovax's approach of using oncolytic viruses and vaccines to activate T-cells to target tumors, rather than directly targeting cancer through surgery, radiation, or chemotherapy.
2) Targovax's two programs - ONCOS, an oncolytic virus, and TG, a therapeutic cancer vaccine - and their clinical development strategies.
3) Early positive results from a Phase I/II trial of ONCOS-102 for malignant pleural mesothelioma, with the drug showing safety, innate and adaptive immune activation, and early signs of clinical activity.
Targovax has two immuno-oncology programs in clinical development - ONCOS and TG. For ONCOS, clinical trials are ongoing in melanoma, mesothelioma, and other solid tumors. Data from the melanoma trial showed ONCOS-102 induced immune activation in the first four patients. The mesothelioma trial safety lead-in was completed without concerns. For TG, clinical data in pancreatic cancer showed one-year survival rates and immune activation. Targovax is listed on the Oslo Stock Exchange with a market capitalization of around NOK 900 million and cash reserves to fund the planned clinical program into 2019.
This investor presentation summarizes the development of Oncolytics Biotech's lead product REOLYSIN, a therapeutic reovirus. Key points include:
1) REOLYSIN has demonstrated statistically significant improvements in overall survival for metastatic breast cancer and doubled two-year survival for metastatic pancreatic cancer.
2) The clinical development plan focuses on combination therapies with chemotherapy, immunotherapy agents like pembrolizumab, and targeted therapies/IMiDs to boost REOLYSIN's mechanism of action.
3) Over 1,100 patients have been treated with REOLYSIN which has shown a good safety profile with no maximum tolerated dose reached and mostly mild side effects.
An oncology-focused immunotherapy company is conducting a Phase 3 clinical trial of its lead product, NeuVax, for the prevention of breast cancer recurrence in early-stage, node-positive patients. The trial is fully enrolled with 758 participants and is evaluating NeuVax compared to placebo on disease-free survival. NeuVax targets the HER2 protein and consists of an HLA-A2/A3-restricted peptide that elicits CD8+ T-cell responses. Previous clinical trials demonstrated NeuVax has a positive safety profile and signals of efficacy in reducing recurrence rates. An interim analysis is upcoming in mid-2016, with final results expected in 2018.
This investor presentation summarizes Oncolytics Biotech's REOLYSIN viral therapy program. It highlights statistically significant increases in overall survival seen in phase 2 trials in metastatic breast cancer and pancreatic cancer. The clinical development plan focuses on three pathways: chemotherapy combinations as the first registration pathway, immunotherapy combinations with agents like pembrolizumab, and targeted therapy combinations using agents like pomalidomide. Safety data from over 1,100 patients shows a good toxicity profile. Manufacturing is established at commercial scale and the company has a strong patent portfolio. The leadership team has extensive experience in oncology drug development.
Merck presented at the 2016 ASCO conference on their oncology strategy and KEYTRUDA program. Key points include:
1) Merck's strategy is to identify patients most likely to benefit from KEYTRUDA, establish KEYTRUDA as a foundation for cancer treatment in monotherapy and combinations, and improve long-term disease control and survival across cancers.
2) KEYTRUDA has shown clinical activity in over 20 tumor types and has over 30 ongoing registration-enabling studies and 100 combination trials. Data at ASCO 2016 showed further progress in combinations and predictive biomarkers.
3) Merck is pursuing a combination strategy with KEYTRUDA and targeted therapies, immunomodulators
Oncolytics Biotech presented their investor presentation which included the following key points:
1) Oncolytics is developing REOLYSIN, a novel immuno-oncology viral agent for systemic administration that exploits cancer cell lysis and anti-tumor immunity.
2) Additional randomized phase 2 clinical trials in 2017 are expected to generate overall survival data in breast cancer, ovarian cancer, non-small cell lung cancer, and colorectal cancer.
3) The clinical development plan focuses on combining REOLYSIN with chemotherapy for late-stage development and establishing it as a backbone agent combined with immunotherapy.
4) Over 900 patients have been treated with REOLYSIN intravenously with no drug
1) Major pharmaceutical companies are rapidly developing immuno-oncology drug combinations in early clinical trials to understand synergies between immunotherapies and targeted therapies. This represents a change in cancer drug development strategies.
2) Companies are taking both diversified and focused approaches to partnering, with external partnerships being important for accessing different asset classes. Having a pipeline of immunotherapies allows testing many combination regimens.
3) The success of early checkpoint inhibitors has convinced most oncology companies to pursue immunotherapies, either through internal programs or partnerships, given immunotherapy's potential as a foundational cancer treatment.
Download Global cancer immunotherapy market outlook 2020KuicK Research
\"Global Cancer Immunotherapy Market Outlook 2020\" Report Highlight:
Introduction & Classification of Cancer Immunotherapy
Global Cancer Immunotherapy Pipeline by Company, Indication & Phase
Marketed Cancer Immunotherapies Clinical Insight & Patent Analysis by Company & Indication
Global Cancer Immunotherapy Pipeline: 1834 Drugs
Marketed Cancer Immunotherapies: 113 Drugs
Cancer Monoclonal Antibodies Pipeline: 622 Cancer mAb
Cancer Vaccines Pipeline: 312 Vaccines
Marketed Cancer mAb: 36 mAb
Marketed Cancer Vaccines: 12 Vaccines
Global cancer immunotherapy market outlook 2020KuicK Research
The document provides an overview of the global cancer immunotherapy market outlook for 2020. It discusses how cancer immunotherapies work by modulating the immune system to treat cancer. The market has seen significant growth with many approved and pipeline immunotherapies across classes like monoclonal antibodies, cytokines, vaccines, and immune checkpoint inhibitors. The market is expected to continue growing in coming years due to increased research and funding leading to new treatment modalities and biomarkers to expand the use of immunotherapies for additional cancer types.
The document summarizes recent news and events in oncology, including:
1) Daiichi Sankyo's acquisition of Plexxikon for its promising drug PLX4032 that targets the BRAF mutation in melanoma.
2) Positive results from Roche's phase 2 trial of its hedgehog pathway inhibitor vismodegib for advanced basal cell carcinoma.
3) How next-generation sequencing is enabling more personalized cancer treatment by matching drugs to patients based on their tumor's molecular profile.
Methanex is the world's largest producer and supplier of methanol. We create value through our leadership in the global production, marketing and delivery of methanol to customers. View our latest Investor Presentation for more details.
UnityNet World Environment Day Abraham Project 2024 Press ReleaseLHelferty
June 12, 2024 UnityNet International (#UNI) World Environment Day Abraham Project 2024 Press Release from Markham / Mississauga, Ontario in the, Greater Tkaronto Bioregion, Canada in the North American Great Lakes Watersheds of North America (Turtle Island).
Cleades Robinson, a respected leader in Philadelphia's police force, is known for his diplomatic and tactful approach, fostering a strong community rapport.
ZKsync airdrop of 3.6 billion ZK tokens is scheduled by ZKsync for next week.pdfSOFTTECHHUB
The world of blockchain and decentralized technologies is about to witness a groundbreaking event. ZKsync, the pioneering Ethereum Layer 2 network, has announced the highly anticipated airdrop of its native token, ZK. This move marks a significant milestone in the protocol's journey, empowering the community to take the reins and shape the future of this revolutionary ecosystem.
2. This report contains certain forward-looking statements based on uncertainty, since they relate to events and depend on
circumstances that will occur in future and which, by their nature, will have an impact on the results of operations and the
financial condition of Targovax. Such forward-looking statements reflect the current views of Targovax and are based on the
information currently available to the company. Targovax cannot give any assurance as to the correctness of such statements.
There are a number of factors that could cause actual results and developments to differ materially from those expressed or
implied in these forward-looking statements. These factors include, among other things, risks or uncertainties associated with the
success of future clinical trials; risks relating to personal injury or death in connection with clinical trials or following
commercialization of the company’s products, and liability in connection therewith; risks relating to the company’s freedom to
operate (competitors patents) in respect of the products it develops; risks of non-approval of patents not yet granted and the
company’s ability to adequately protect its intellectual property and know-how; risks relating to obtaining regulatory approval and
other regulatory risks relating to the development and future commercialization of the company’s products; risks that research
and development will not yield new products that achieve commercial success; risks relating to the company’s ability to
successfully commercialize and gain market acceptance for Targovax’s products; risks relating to the future development of the
pricing environment and/or regulations for pharmaceutical products; risks relating to the company’s ability to secure additional
financing in the future, which may not be available on favorable terms or at all; risks relating to currency fluctuations; risks
associated with technological development, growth management, general economic and business conditions; risks relating to the
company’s ability to retain key personnel; and risks relating to the impact of competition.
Important
NOTICE AND DISCLAIMER
4. 4
From a sequential treatment strategy
directly targeting the cancer…
1
Surgery
When possible,
surgical resection to
remove the tumor
2
Radiotherapy
Tumor irradiation
to shrink
tumor volume
3
Chemotherapy
Cornerstone treatment
in most cancer forms
6. 6
Mode of action
IMMUNE ACTIVATORS TURN COLD TUMORS HOT
Example from Targovax Phase I trial – Ovarian cancer patient
Before injection of
oncolytic virus
“Cold tumor”
No T-cell infiltration
After injection of
oncolytic virus
“Hot tumor”
Full T-cell infiltration
CD8+ T-cell
Recognizes
and destroys
cancer cells
7. 7
Targovax has two programs in clinical development, with an
ONCOLYTIC VIRUS LEAD PRODUCT CANDIDATE
ONCOS
Oncolytic virus
TG
Neoantigen
vaccine
Lead product candidate
o Genetically armed adenovirus
o Alerts the immune system to the
presence of cancer antigens
o Induces T-cells specific to
the patients’ tumor
o 4 ongoing trials
Pipeline product
o Shared neoantigen, therapeutic
cancer vaccine
o Triggers the immune system to
recognize mutant RAS cancers
Activates the
immune system
Triggers patient-
specific responses
No need for
individualization
8. 8
Major deals over the past 6 months are driving increasing
INDUSTRY INTEREST IN ONCOLYTIC VIRUSES
Type of deal Deal value
M&A
Phase I/II
oncolytic virus
BD partnership
IV delivered
oncolytic virus
Acquirer Target
USD 400m
up-front cash
USD 140m
up-front cash
Up to USD 1b
total value
M&A
Pre-clinical
oncolytic virus
USD 15m
milestone payment
Up to USD 1b
total value
10. 10
ONCOS-102 Phase I trial design:
o 12 patients, 7 different solid tumors
o No other treatment options left
o Monotherapy 9 injections
Pre-treatment Post-treatment
Cold tumor turned hot
CD8+ T-cell staining
ONCOS-102
Phase I single agent proof of concept
IMMUNE ACTIVATION
DEMONSTRATED
Top-line results:
o 100% innate immune activation
o 11/12 patients increase in TILs
o Abscopal effect
o Tumor specific T-cells in blood
o Correlation with survival
11. Case example
o Ovarian cancer
o Failed on 5 chemotherapies
o Tumor specific T-cells after 2 years
o Stable disease for 3 years
o Survived 3.5 years
11
ONCOS-102
Phase I single agent proof of concept
CD8+ T-CELL INFILTRATION
CORRELATES WITH SURVIVAL
11
Fold-change CD8+ T-cell count vs. survival
CD8+fold-changefrombaseline
Overall survival (months)
0 40
0.1
10,000
1
1,000
100
10
5 10 15 20
r = 0.75 p = 0.005
12. 12
ONCOS
CLINICAL DEVELOPMENT STRATEGY
Target launch
indication
o Orphan drug
o Addition to SoC
o Controlled trial
o 15,000 incidents
Indications with
limited CPI effect
o Melanoma Ph I
o Combo w/PD-1
o >100,000 incidents
Peritoneal
malignancies
o Ovarian/colorectal
o Ph I/II
o Combo w/PD-L1
o >100,000 incidents
Double transgene
adenoviruses
o Novel targets
o In vivo testing
1
Mesothelioma
Orphan disease
2
CPI synergy
Intra-tumoral
3
CPI synergy
Intra-peritoneal
4
Next generation
ONCOS viruses
SOURCE: Global Data, EU big 5 + US
13. 13
Compassionate use
program
115 patients
o Ovarian and colorectal cancers
o Combination with durvalumab
o Intraperitoneal administration
o Collaboration with AZ, CRI,
Ludwig
Phase I trial
12 patients
7 indications
Peritoneal cancer
Phase I/II
up to 78 patients
Melanoma
Phase I
12 patients
Mesothelioma
Phase I/II -
randomized
30 patients
o Combination with pembrolizumab
o PoC in CPI refractory patients
o Orphan indication
o Combination with SoC chemo
o Randomized vs. SoC
ONCOS
CLINICAL PROGRAM OVERVIEW
Completed trials
Ongoing trials
Trials sponsored
by partner
14. Rationale for ONCOS-102 opportunity in mesothelioma
14
ONCOS-102 has the potential to become a breakthrough
IN THE TREATMENT OF MESOTHELIOMA
Become frontline therapy
o Currently testing efficacy
in combination with SoC
chemotherapy in both 1st
and 2nd line in 30 patients
randomized Phase I/II trial
o Good safety profile
Orphan Drug Designation
o High unmet medical need,
ONCOS-102 has ODD
o Opportunity for priority
regulatory review
o 7 year market exclusivity
in the US and 10 years in
the EU
Limited competition
o CPIs show some early
signs of efficacy, but are
potential ONCOS-102
combinations, rather than
competitors
o No/few competing viruses
and vaccines in clinical
development
15. 15
ONCOS-102 in malignant pleural mesothelioma
PHASE I/II STUDY DESIGN IN COMBINATION WITH SoC
Safety lead-in (n=6)
ONCOS-102
plus SoC chemotherapy
(6 cycles)
Experimental group
(n=14)
ONCOS-102 (6 administrations)
SoC (6 cycles)
Non-randomized
Control group (n=10)
SoC (6 cycles)
Randomized
Safety lead-in completed
Randomized part
currently enrolling
Patient population
Advanced malignant
pleural mesothelioma
1st line / 2nd line
16. 16
ONCOS-102 in malignant pleural mesothelioma
SIGNAL OF EFFICACY IN THE FIRST 6 PATIENTS
1
Safety
2
Innate immune
activation
3
Adaptive immune
activation
4
Clinical activity
✓ ONCOS-102 well-
tolerated in
combination with
chemotherapy
✓ Systemic
increase of pro-
inflammatory
cytokines in 6/6
patients (IL-6,
TNFα and IFNγ)
✓ Increase in tumor
infiltration of
CD4+ and CD8+
T cells in 3/4
patients
✓ Clinical activity
seen in 3/6
patients after 6
months
✓ 50% disease
control rate
17. 17
ONCOS-102 in malignant pleural mesothelioma
DEVELOPMENT STRATEGY AND INDICATIVE TIMELINES
2018 2019 2020 2021 2022
o Randomized ORR and OS
data 30 patients
o Decide on possible CPI
combination arm
o EMA & FDA advisory
meetings
o Randomized ORR and OS
data 90 patients
o Potentially use as basis
for a submission for
conditional approval
o Potentially start Phase III
OS trial for full MAA
Ongoing
Phase I/II, randomized
30 patients
Planned
Expansion of randomized Phase II
~60 additional patients (N=90)
Future
Phase III
n=TBD
19. Frequency of RAS mutations
Global cancer incidents per 10,000
(xx) = no. of cancer patients
19
The RAS gene is mutated in
90% OF PANCREATIC AND 50% OF COLORECTAL CANCERS
0
High
Med
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15
Low
Pancreas
(340,000)
Gallbladder
(180,000)
Melanoma of skin
(230,000)
Prostate
(1,130,000)
Colorectal
(1,360,000)
Lung
(1,820,000)
o RAS mutations are oncogenic and
result in uncontrolled cell
division
o There are no existing therapies
targeting RAS mutations
o Targovax’ TG program is a unique
vaccine approach for mutant
RAS cancer
Fernandez-Medarde; RAS in Cancer and Developmental Diseases; Genes & Cancer. 2011;2(3)
20. Mutated RAS is a well-defined, cancer-
specific neo-antigen, driving the cancer
TG peptides are clinically proven to induce
both CD4+ and CD8+ mutRAS T-cells
Initial focus on resected patients,
with stronger immune system
Target often poorly defined and not
cancer specific, mainly TAAs
20
WHY THE TG APPROACH MAY WORK
where other cancer vaccines have failed
The TG approachHistorical lessons learned
No or insufficient immune activation
of the adaptive immune system
Most clinical trials have been done in
advanced disease
21. 21
TG01 indication
o Ph I/II completed
o Next steps
currently being
reassessed
o ~40 000 incidents
TG02 lead indication
o Ph I trial ongoing
o 50% mutRAS
o ~0.5m incidents
TG02 potential
future indication
o 30% mutRAS
o ~0.5m incidents
TG02 + TG03 long-
term potential
o Up to 30% of all
cancer patients
1
Resected pan-
creatic cancer
2
Colorectal
cancer
3
Lung cancer
(NSCLC)
4
All mutRAS
cancers
Source: Global data, Riva et al. Plos One 2017 Estimated total addressable patient number with RAS mutations in US, EU and China
TG
CLINICAL DEVELOPMENT STRATEGY
22. 22
TG CLINICAL PROGRAM OVERVIEW
Phase I & II
>200 patients
o Currently reassessing
opportunities for new trials to
drive value creation on TG
program
Phase I/II
Resected
pancreatic cancer
32 patients
TBD
Colorectal -
TG02
Phase I
o Biomarker study
o Combination w/KEYTRUDA®
Completed trials Ongoing trials Planned trial
24. Cancer Indication
ONCOS-102
Mesothelioma
Melanoma
Peritoneal malignancies
Collaboration w/CRI,
Ludwig & MedImmune
Prostate
Collab. w/Sotio
TG
Resected Pancreas
Colorectal
24
Targovax overall
CLINICAL PROGRAM TIMELINES
Interim data Clinical, immune and safety data
2018 2019
H1 H2 H1 H2
2020
H1
Phase l/II
Phase lb
Phase l
Phase lb/II
Phase I/II
Phase l
Ongoing clinical trials,
Targovax sponsored
Ongoing clinical trials,
partner sponsored
25. ACTIVATING THE PATIENT`S IMMUNE SYSTEM
to fight cancer
Oncolytic virus
lead product
Strong single agent data
Several upcoming data points
Defined path
to market
Aim to become frontline
treatment in mesothelioma
Orphan drug designation
Innovative
pipeline
Next gen double transgene
viruses in testing
Signal of efficacy for mutRAS
neoantigen vaccine
27. Operations The share
TARGOVAX HAS A SOUND FINANCIAL POSITION
with cash to complete the planned clinical program well into 2019
229
NOK million
29
USD million
Cash end of Q1 - Mar 31st 2018
-32
NOK million
-4
USD million
Net cash flow - total Q1
113
NOK million
15
USD million
Annual run rate - last four quarters
900
NOK million
110
USD million
Market Cap - at share price NOK ~17
3
NOK million
0.4
USD million
Daily turnover - rolling 6 month avg.
DNB, ABG Sundal Collier, Arctic,
Redeye, Norske Aksjeanalyser, Edison
Analyst coverage
28. 28
Key international investors
participating in PP 2017
Nyenburgh (NL)
Trium (UK)
Millenium Capital Partners (UK)
Interogo (SWE)
AP3 (SWE)
Aramea AM (DE)
THE SHAREHOLDER BASE IS STRONG
with a mix of specialist, generalist and retail investors
Shares and options
57.4m shares fully diluted
o Average strike price on options ~NOK 20
o Total dilutive effect of options is 8.1%
52.6m ordinary shares
o Management ownership: 0.3%
o >4,100 shareholders
Shareholder No. of shares Ownership
1 HealthCap 12 405 584 23,6 %
2 Nordea 4 626 839 8,8 %
3 RadForsk 4 427 255 8,4 %
4 KLP 2 117 144 4,0 %
5 Statoil 1 187 981 2,3 %
6 Thorendahl Invest AS 1 000 000 1,9 %
7 Danske Bank (nom.) 828 250 1,6 %
8 Timmuno AS 728 601 1,4 %
9 Prieta AS 720 000 1,4 %
10 Sundt AS 500 000 1,0 %
Other shareholders (~4108)20 806 325 39,5 %
Total 52 609 867 100,0 %
Estimated ownership